drugset / Trial / NCT05333809
Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, multi-center, phase Ⅱ study. This study will evaluate the efficacy and safety of pembrolizumab in combination with disitamab vedotin in subject with HER2-expressing metastatic Colorectal Cancer (mCRC).
Timeline
- Start
- 2022-07-01
- Primary completion
- 2024-07-01
- Completion
- 2025-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Disitamab Vedotin | Monoclonal antibody | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |